Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced full year 2025 financial results.Reported record full year of 2025 revenue of $32.0 million, an increase of approximately 27% over full year of 2024. Cash, cash equivalents, and marketable securities (“Total Cash”) of $11.6 million at December...

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 – – Presentation of additional Phase 3 ONWARD1 and ONWARD2 data at AAD 2026 – – Completed an upsized public offering raising $345.1 million in gross proceeds in Jan 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the year ended...

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile Completed an oversubscribed $160 million PIPE financing led by leading healthcare investors in March 2026, strengthens balance sheet to support NDV-01 Phase 3 development On track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 Cash balance of $93.0 million as of December 31, 2025, plus gross proceeds of $160 million from March 2026 PIPE expected to fund operations through 2029, including completion of the NDV-01 RESCUE program Management to host a conference call and webcast today at 4:30 PM ETCORAL GABLES, Fla., March 19, 2026 (GLOBE...

NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. “We are excited to enter 2026 with significant momentum as we continue to advance the development of our ProTide pipeline with the aim to deliver significantly improved treatment outcomes for patients with cancer,” said Hugh S. Griffith, NuCana’s Chief...

Paris, 19 March 2026 AVAILABILITY OF THE 2025 UNIVERSAL REGISTRATION DOCUMENTINCLUDING THE ANNUAL FINANCIAL REPORT Hermès International filed its 2025 Universal Registration Document with the Financial Markets Authority (AMF), on 19 March 2026, in ESEF format. It is available to the public under current regulatory conditions and may be found on finance.hermes.com (under “Investors section” > “Publications” and “Regulated information”) The universal registration document comprises:the annual activity report; the parent company and consolidated financial statements for 2025; the report on sustainability information; the Supervisory Board’s report on the corporate governance; a description of the share buyback programme prepared pursuant to Articles 241-2 and 241-3 of the General Regulation of the Financial Markets Authority (AMF); the...

SHANGHAI, March 19, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, reported its 2025 annual results, posting strong revenue growth and achieving full-year profitability, as its AI-enabled chronic disease management model continues to scale. Total revenue rose 30.2% year on year to RMB 3.53 billion in 2025, driven by steady growth in its consumer-facing businesses, including comprehensive medical services and online retail pharmacy services, which collectively grew by approximately 30%. The Company also recorded net profit of RMB 12 million, exceeding market expectations and marking a turnaround from a net loss in 2024. Adjusted net profit was up 19%, reaching RMB 20.4 million. This strong performance reflects continued momentum in...

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-2027 LONDON, March 19, 2026 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments. “In collaboration with our partner Ultragenyx, we have analysed a significant part of the data from the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta and continue to develop our understanding of the fracture data and the patient reported outcomes (PROs), especially in patients aged 2–18 years...

Revenues for fourth quarter and full year 2025 of $11.8 million and $40.7 million, up 60% and 28% respectively, year-over-year; the strong growth driven by accelerating AI demand Investing strongly in enhancing capabilities, while remaining profitable with FY 2025 net profit of $1.0 million and adjusted EBITDA of $4.4 million TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Alarum Technologies Ltd. (Nasdaq: ALAR, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights of Full Year 20252025 revenues of $40.7 million, up 28% year-over-year compared to $31.8 million in 2024. Gross margin of 58.5% compared with 75.1% in 2024, reflecting strategic investments in infrastructure...

DALLAS, March 19, 2026 (GLOBE NEWSWIRE) — Strive, Inc. (Nasdaq: ASST; SATA) (“Strive” or the “Company”) today announced its financial results for the fourth quarter ended December 31, 2025. Key Highlights Since Strive’s Public Listing in September 2025:Accumulated a total of 13,628 bitcoin as of March 17, 2026.5,886 bitcoin from initial PIPE proceeds and 351 exchange. 5,048 bitcoin from acquisition of Semler Scientific, Inc. 2,694 bitcoin from other capital markets activity, including SATA IPO and follow-on, ASST ATM, and SATA ATM.Achieved a Bitcoin Yield of 22.2% in Q4 2025 and 13.8% QTD (as of March 17, 2026) in Q1 2026. Generated a Bitcoin Gain of ₿1,305 BTC in Q4 2025 and ₿1,050 QTD (as of March 17, 2026) in Q1 2026. Generated a Bitcoin $ Gain of $114.3 million in Q4 2025 and $78.2 million QTD (as of March 17, 2026)...

TEJON RANCH, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today announced financial results for the fourth quarter and year-ended December 31, 2025. Fourth-Quarter 2025 Financial HighlightsNet income attributable to common stockholders decreased by $2.9 million to $1.6 million ($0.06/share basic and diluted), compared to $4.5 million ($0.17/share) in fourth quarter of 2024. Revenues and other income, including equity in earnings from unconsolidated joint ventures, increased 8% to $23.3 million, compared to $21.6 million. Farming segment revenues increased 26% to $12.2 million, compared to $9.7 million. Adjusted EBITDA, a non-GAAP measure, increased 9% to $11.4 million, compared to $10.5...